Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=68 Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Phase 2 N=79 Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Phase 2 N=20 Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Primary: Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection — 16 Participants
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
Phase 2 N=28 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Phase 2 N=64 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients
Phase 2 N=40 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
Phase 2 N=26 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Cancer Metastatic
Primary: Safety as Measured by Number of Participants With Drug-related Adverse Events — 19; 2 Participants
Phase 2 N=10 Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants
N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Phase 2 N=30 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Phase 2 N=46 Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 0; 2 participants
Early Phase 1 N=16 Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Oral Squamous Cell Carcinoma
Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response — 9; 6 Participants
Phase 1 N=147 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Phase 2 N=24 Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Phase 2 N=39 Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma · Recurrent Skin Squamous Cell Carcinoma
Primary: Overall Response Rate — 3 Participants
Phase 2 N=267 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Primary: Objective Response Rate at 6 Months — 7.7; 9.2; 1.6 % participants
Phase 2 N=34 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Phase 2 N=12 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants